Frozen Addicts AADC
Medicine

From Frozen Addicts to Gene Therapy

Sometimes, the most fascinating stories about medical breakthroughs come from the most unexpected places. In this case, it was over dinner in Taiwan, celebrating the journey of AADC gene therapy from clinical trials to approval.

During the evening, I had the pleasure of speaking with Professor Shin-ichi Muramatsu from Japan, one of the researchers who helped advance gene therapy for neurological disorders. As we discussed the history behind this remarkable treatment, he shared a story that sounded more like the plot of a science fiction movie than medical research.

It involved illegal drugs, people suddenly becoming frozen in their own bodies, and monkeys that would eventually help scientists understand how to restore dopamine production.

Naturally, he had my attention. I certainly wasn’t expecting a story involving synthetic heroin over dinner!

The mysterious case of the frozen addicts

illegal synthetic opioid
illegal synthetic opioid

Our story begins in California during the early 1980s. Someone manufacturing an illegal synthetic opioid made a dangerous chemical mistake. The resulting substance contained a contaminant called MPTP.

When several people injected the contaminated drug, something terrifying happened. Within days, previously healthy young adults developed severe Parkinson-like symptoms. Some became almost completely unable to move or speak.

Imagine being in your twenties and suddenly developing symptoms normally associated with advanced Parkinson’s disease. The cases became famously known as the “Frozen Addicts.”

Scientists eventually discovered that MPTP was converted inside the brain into a toxin called MPP+, which damaged neurons responsible for producing dopamine.

Although the incident was tragic, it gave researchers an unexpected opportunity to better understand the brain’s dopamine system.

But how did the monkey get AADC deficiency?

rhesus macaque aadc study
The early AADC gene therapy experiments used macaque monkeys.

This was the part of Professor Muramatsu’s story that particularly interested me. Scientists began using MPTP to create experimental models of Parkinson’s disease in monkeys.

Now, before anyone imagines a monkey being born with or even created to have AADC deficiency, that wasn’t the case. These monkeys did not have the inherited genetic condition affecting our daughter, Rylae-Ann. Instead, researchers used MPTP to damage dopamine-producing neurons, creating symptoms resembling Parkinson’s disease.

This allowed scientists to investigate whether gene therapy could help restore the brain’s ability to produce dopamine. The approach involved using a modified virus to deliver genes encoding enzymes involved in dopamine synthesis into an area of the brain called the putamen. One of those enzymes was AADC.

And something remarkable happened. The monkeys demonstrated improvements in movement and dopamine-related function.

In research involving Professor Muramatsu and his colleagues, one monkey continued showing benefits 15 years after receiving gene therapy. The researchers also confirmed that the brain was still expressing the delivered genes.

Fifteen years! Considering how quickly technology changes, that’s practically several generations in medical research.

From Parkinson’s research to AADC deficiency

L-Dopa Chemical Compound
The glowing molecular structure of L-DOPA (Levodopa)—the gold-standard pharmaceutical compound used to manage and restore neurotransmitter balance in Parkinson’s disease. As a direct metabolic precursor to dopamine, this amino acid derivative is uniquely capable of crossing the blood-brain barrier to alleviate motor symptoms.

Here is where the story becomes personal.

Parkinson’s disease and AADC deficiency are very different conditions. Parkinson’s involves the loss of dopamine-producing neurons, while children with AADC deficiency are born with genetic changes that prevent their bodies from producing sufficient amounts of the AADC enzyme. However, both conditions involve the dopamine pathway.

For children with AADC deficiency, the missing or malfunctioning enzyme means the brain struggles to convert L-DOPA into dopamine. AADC is also essential for serotonin production.

Researchers realized that delivering a functional AADC gene directly into the brain might allow certain brain cells to produce the enzyme that children like Rylae-Ann were missing.

The monkey research did not prove that gene therapy would work in children with AADC deficiency. However, it helped establish that researchers could deliver genes involved in dopamine production into the brain and keep them active for many years. The story on how this connection was made deserves its own post.

Professor Muramatsu’s research was an important stepping stone toward human clinical trials.

A dinner conversation that came full circle

Rylae-Ann with Prof. Muramatsu in Taiwan 2024
Rylae-Ann with Prof. Muramatsu in Taiwan 2024

As I listened to Professor Muramatsu, I couldn’t help thinking about how far this research had traveled.

What began with a tragic drug-related incident in California contributed to Parkinson’s research, which helped advance gene therapy techniques that would eventually offer new possibilities for children with AADC deficiency.

In November 2019, our daughter Rylae-Ann received investigational gene therapy in Taiwan. At the time, we were simply parents hoping to give our daughter an opportunity for a better quality of life. We certainly weren’t thinking about monkeys, MPTP, or experiments conducted decades earlier.

Yet there we were, years later, celebrating the approval of AADC gene therapy in Taiwan and listening to one of the scientists involved in its development explain an extraordinary part of its history.

Of course, animal research also raises important ethical questions. These experiments involved deliberately causing neurological damage, something that should never be treated lightly. Scientific progress requires both rigorous research and serious consideration of animal welfare.

Still, the conversation reminded me that medical breakthroughs are rarely the result of one discovery or one individual. They are built upon decades of research, unexpected findings, failed experiments, and scientists willing to explore new possibilities.

For our family, the connection between those early experiments and Rylae-Ann’s journey was especially meaningful.

The next time someone asks me how AADC gene therapy became possible, I might just begin with a rather unexpected sentence:

“Well, it all started with a group of frozen drug users and some monkeys.”

That should certainly get their attention. And if Professor Muramatsu ever shares another story like this over dinner, I’ll be making sure to bring a notebook.